Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.45 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089161 | 0.98 | HDAC1 (0.56) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL23176839 | 0.98 | HDAC1 (0.56) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL1047276 | 0.98 | HDAC1 (0.56) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL1079525 | 0.98 | HDAC1 (0.56) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL2652908 | 0.94 | MAOB (0.58) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL81840 | 0.94 | TAAR1 (0.57) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL2653733 | 0.93 | MAOB (0.56) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL2652794 | 0.93 | MAOB (0.56) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL2653224 | 0.88 | MAOB (0.59) | HDAC1HDAC8TAAR1PTPN2PTPN1 | |
| SCHEMBL6022637 | 0.88 | HDAC1 (0.51) | HDAC1HDAC8TAAR1PTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361249-A1 | SURFACE TREATMENT AGENT | DAIKIN INDUSTRIES, LTD. (JP) | 2025-11-27 | — | — | US | disclosed |
| EP-4644398-A1 | SURFACE TREATMENT AGENT | Daikin Industries, Ltd. (JP) | 2025-11-05 | — | — | EP | disclosed |
| US-12234229-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-02-25 | — | — | US | disclosed |
| WO-2024172036-A1 | SURFACE TREATMENT AGENT | ダイキン工業株式会社 | 2024-08-22 | — | — | WO | disclosed |
| US-20230050649-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-02-16 | — | — | US | disclosed |
| US-20230050649-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-02-16 | — | — | US | disclosed |
| EP-3914351-A1 | CARBAMATE DERIVATIVES AND USES THEREOF | Nodthera Limited (GB) | 2021-12-01 | — | — | EP | disclosed |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | U niversity of Virginia Patent Foundation (US) | 2021-11-23 | — | — | US | disclosed |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | U niversity of Virginia Patent Foundation (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3436451-B1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-09-29 | — | — | EP | disclosed |
| WO-2008016692-A2 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| EP-1689715-A4 | TUBULIN INHIBITORS | CYTOPIA RES PTY LTD (AU) | 2008-01-23 | — | — | EP | disclosed |
| EP-1569917-A4 | PYRAZINE-BASED TUBULIN INHIBITORS | CYTOPIA PTY LTD (AU) | 2007-08-15 | — | — | EP | disclosed |
| EP-1689715-A1 | TUBULIN INHIBITORS | Cytopia Research Pty Ltd (AU) | 2006-08-16 | — | — | EP | disclosed |
| EP-1656141-A1 | TREATMENT FOR ALZHEIMER S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME LTD. (GB) | 2006-05-17 | — | — | EP | disclosed |
| EP-1569917-A1 | PYRAZINE-BASED TUBULIN INHIBITORS | Cytopia PTY Ltd (AU) | 2005-09-07 | — | — | EP | disclosed |
| WO-2005054199-A1 | TUBULIN INHIBITORS | CYTOPIA RESEARCH PTY LTD (AU) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005013985-A1 | TREATMENT FOR ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004052868-A1 | PYRAZINE-BASED TUBULIN INHIBITORS | CYTOPIA PTY LTD (AU) | 2004-06-24 | — | — | WO | disclosed |
| WO-2003042206-A1 | PYRIDINONE AND PYRIMIDINONE COMPOUNDS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234229-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | SPHK1, SPHK2, S1PR2 | HDAC1 1189/4885HDAC8 2288/4885TAAR1 1734/4885 |
| US-20230050649-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHK1, SPHK2, S1PR2 | HDAC1 1189/4885HDAC8 2288/4885TAAR1 1734/4885 |
| US-20250361249-A1 | SURFACE TREATMENT AGENT | ITGA1, ITGB1, GDI1 | HDAC1 140/4885HDAC8 1056/4885TAAR1 417/4885 |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | SPHK1, SPHK2, S1PR2 | HDAC1 1189/4885HDAC8 2288/4885TAAR1 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.